Recent reports have demonstrated that an exosome-based dual-delivery biosystem enhances PDAC immunotherapy and restores tumor immunosuppression in M2-like tumor-associated macrophages by disrupting the galectin-9/dectin-1 axis [153]. This evidence concerns the gene LGALS9 and neoplasm.